You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 618 Phase 1 clinical trial evaluating the safety, biologic and anti-tumor activity of the novel STING agonist IMSA101 administered both as monotherapy and in combination with PD-(L)1 checkpoint inhibitors

Article Text

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial Completed
618 Phase 1 clinical trial evaluating the safety, biologic and anti-tumor activity of the novel STING agonist IMSA101 administered both as monotherapy and in combination with PD-(L)1 checkpoint inhibitors

https://doi.org/10.1136/jitc-2023-SITC2023.0618

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.